Andrew Farland, MD
Hematology & Oncology · Winston Salem, NCNPI 1750551453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Sanofi at 26.8% of the total. 2023 is the largest year on record at $187, 2.3 times the $83 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in NC, where the typical reported total is $1,703.
Across 5 payments — averaging $99.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$133
- Sanofi-aventis U.S. LLC$98
- Rigel Pharmaceuticals, Inc.$94
- E.r. Squibb & Sons, L.L.C.$90
- AstraZeneca$83
Across 15 payments — averaging $1514.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$13K
- AstraZeneca$6K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
What the payments were for
- Food & beverage$496100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $133 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Rigel Pharmaceuticals, Inc. | 1 | $94 |
| E.r. Squibb & Sons, L.L.C. | 1 | $90 |
| AstraZeneca | 1 | $83 |
How this compares
$496 in reported general payments places this provider in the 30th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $47,994 |
| XareltoRivaroxaban | 17 | $25,641 |
| Hydroxyurea | 18 | $640 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Winston Salem
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Caio Max Rocha LimaWinston Salem$110K
- Timothy PardeeWinston Salem$68K
- Leon Bernal-MizrachiWinston Salem$62K
- Matthew WieduwiltWinston Salem$36K
- John McKayWinston Salem$22K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.